RBN Meditech Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: RBN Meditech Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $70.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

RBN Meditech Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $70.1K Trade | TransData Nexus

RBN Meditech Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $70.1K Total Trade · DGFT Verified

RBN Meditech Private Limited is an Indian pharmaceutical exporter with a total trade value of $70.1K across 2 products in 1 therapeutic categories. Based on 18 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ibrutinib ($41.7K), Nivolumab ($28.4K), .

RBN Meditech Private Limited — Export Portfolio & Destination Treemap

RBN Meditech Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is RBN Meditech Private Limited? — Company Overview & Market Position

RBN Meditech Private Limited, established on December 1, 2022, is a privately held company headquartered in Pune, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U24304PN2022PTC216606 and is registered with the Registrar of Companies (RoC) Pune. With an authorized capital of ₹500,000 and a paid-up capital of ₹100,000, RBN Meditech is classified as a private limited company.

The company's registered office is located at 988/3, Sadashiv Peth, Shop No. A-1, Near Dnyan-Prabodhini, Pune, Maharashtra, 411030, India. RBN Meditech specializes in the wholesale import and export of pharmaceutical and surgical products, including disinfectants, disposable garments, and specialized hemodialysis consumables. As of March 2024, the company reported a total export value of $70,000 USD across 18 shipments, focusing on advanced oncology formulations.

What Does RBN Meditech Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ibrutinib$41.7K 2

Product Portfolio — Top 2 by Export Value

RBN Meditech Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ibrutinib	Advanced Oncology	$41.7K	6	4.1%	3
2	Nivolumab	Advanced Oncology	$28.4K	12	1.2%	6

RBN Meditech Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $70.1K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

RBN Meditech Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

RBN Meditech Private Limited's manufacturing facilities are located in Pune, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding manufacturing capacities and specializations are not publicly disclosed, the company's product portfolio indicates a focus on advanced oncology formulations. The manufacturing processes adhere to international standards to ensure product quality and safety.

3Key Leadership

The leadership team of RBN Meditech Private Limited comprises:

Akshay Vijay Nawadkar: Managing Director, appointed on December 1, 2022.

Maya Ishwar Patil: Director, appointed on December 1, 2022.

Leena Manohar Patil: Director, appointed on September 20, 2024.

The leadership team is responsible for steering the company's strategic direction and ensuring compliance with regulatory standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does RBN Meditech Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

RBN Meditech Private Limited's export activities are primarily focused on the advanced oncology therapeutic category, with significant exports of Ibrutinib and Nivolumab. The company's export data indicates a concentration in this therapeutic area, with 100% of its exports in advanced oncology. While specific details regarding regulatory filings, approvals, and market access in the US, EU, UK, Australia, and Japan are not publicly available, the company's adherence to international standards suggests a commitment to meeting regulatory requirements in these markets.

2Emerging Markets

RBN Meditech Private Limited's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on advanced oncology formulations may present opportunities for expansion into these regions, especially given the increasing demand for specialized medical treatments. Achieving WHO prequalification could further enhance the company's access to these markets.

3Geographic Strategy

RBN Meditech's export data indicates a concentration in the advanced oncology therapeutic category, with 100% of its exports in this area. This focus suggests a strategic direction aimed at establishing a strong presence in the oncology market. While the company's export data does not specify geographic diversification, the concentration in advanced oncology may indicate a targeted approach to meet the needs of specific markets.

RBN Meditech Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding RBN Meditech Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates a focus on advanced oncology formulations, which may require compliance with FDA regulations for market access in the United States. The absence of publicly available information suggests that the company may not currently have FDA approvals or registrations.

2WHO & EU GMP

RBN Meditech Private Limited's export data does not provide specific information regarding WHO prequalification or EU Good Manufacturing Practice (GMP) certifications. Achieving WHO prequalification could enhance the company's credibility and facilitate access to international markets. Similarly, obtaining EU GMP certification would be beneficial for market entry into European countries.

3CDSCO & Indian Regulatory

RBN Meditech Private Limited's export data does not specify details regarding its compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, state drug controller approvals, or export No Objection Certificates (NOCs). The company's focus on advanced oncology formulations suggests adherence to CDSCO guidelines for manufacturing and export. However, specific regulatory approvals are not publicly disclosed.

RBN Meditech Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

RBN Meditech Private Limited operates in the competitive pharmaceutical export market, focusing on advanced oncology formulations. While specific competitors are not identified in the available data, the company's emphasis on high-quality products and adherence to international standards positions it favorably in the market. The concentration in advanced oncology may limit direct competition but also exposes the company to market risks associated with this niche.

2Key Differentiators

RBN Meditech Private Limited's key differentiators include its specialization in advanced oncology formulations, commitment to product quality, and adherence to international standards. The company's focus on high-quality products and customer-centric approach enhances its competitive advantage in the pharmaceutical export market.

3Strategic Position

RBN Meditech Private Limited's strategic direction appears to be focused on the export of advanced oncology formulations, with a concentration on products like Ibrutinib and Nivolumab. The company's adherence to international standards and commitment to product quality suggest a strategy aimed at establishing a strong presence in the oncology market. Future outlooks may include expansion into emerging markets and diversification of the product portfolio.

Buyer Due Diligence Brief — Evaluating RBN Meditech Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

RBN Meditech Private Limited's export data indicates a total export value of $70,000 USD across 18 shipments, focusing on advanced oncology formulations. The company's adherence to international standards and commitment to product quality suggest reliability in its export operations. However, the concentration in a single therapeutic category may pose risks related to market fluctuations.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practices. This can be verified through the WHO's official website or by requesting certification documents from the company.

Frequently Asked Questions — RBN Meditech Private Limited

How many pharmaceutical products does RBN Meditech Private Limited export from India?

RBN Meditech Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Ibrutinib ($41.7K), Nivolumab ($28.4K). Total export value is $70.1K.

What is RBN Meditech Private Limited's total pharmaceutical export value?

RBN Meditech Private Limited's total pharmaceutical export value is $70.1K, based on 18 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does RBN Meditech Private Limited cover?

RBN Meditech Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full RBN Meditech Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.